STOCKHOLM, Jan. 15, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical pharmacokinetic (PK) data from the first study with fostroxacitabine bralpamide (fostrox) (NCT03781934) will be presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit in February 22-24, 2024 in Rotterdam..

斯德哥尔摩，2024年1月15日/PRNewswire/--Medivir AB（纳斯达克-斯德哥尔摩：MVIR），一家制药公司，专注于在医疗需求未得到满足的领域开发创新的癌症治疗方法，今天宣布，2024年2月22日至24日在鹿特丹举行的欧洲肝病研究协会（EASL）肝癌峰会上，将提交福斯特罗西他滨-布拉帕胺（fostrox）（NCT03781934）首次研究的临床药代动力学（PK）数据。。

The abstract, titled 'Population pharmacokinetic modeling of orally administered fostroxacitabine bralpamide (fostrox, MIV-818) and its metabolite troxacitabine in a phase I/IIa liver cancer study' will be presented at the conference by Karin Tunblad PhD, Project Director for fostrox at Medivir. The presentation will include pharmacokinetic results from 42 patients in the phase I/IIa clinical study with fostrox monotherapy and the fostrox + Lenvima® combination, supporting regulatory interactions and further strengthening the continued development of fostrox in patients with hepatocellular carcinoma (HCC)..

这篇题为“口服福司他滨bralpamide（fostrox，MIV-818）及其代谢物曲西他滨在I/IIa期肝癌研究中的群体药代动力学建模”的摘要将由Medivir fostrox项目总监Karin Tunblad博士在会议上介绍。该演讲将包括fostrox单药治疗和fostrox+Lenvima®组合的I/IIa期临床研究中42名患者的药代动力学结果，支持调节相互作用，并进一步加强肝细胞癌（HCC）患者fostrox的持续发展。。

The abstract and the poster will be available on Medivir's website after the presentation.

演示后，将在Medivir的网站上提供摘要和海报。

For additional information, please contact;

有关更多信息，请联系；

Magnus Christensen, CFO, Medivir ABTelephone: +46 8 5468 3100.E-mail: [email protected]

麦迪韦公司首席财务官Magnus Christensen电话：+46 8 5468 3100。电子邮件：[受电子邮件保护]

About fostrox

关于fostrox

Fostrox is a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. This is achieved by coupling an active chemotherapy (troxacitabine) with a prodrug tail. The prodrug design enables fostrox to be administered orally and travel directly to the liver where the active substance is released locally in the liver.

Fostrox是一种智能化学疗法，可选择性地将细胞杀伤化合物递送至肿瘤，同时最大程度地减少对正常细胞的有害影响。这是通过将活性化疗（曲西他滨）与前药尾部偶联来实现的。前药设计使fostrox能够口服给药，并直接进入肝脏，活性物质在肝脏局部释放。

With this unique mechanism, fostrox has the potential to become the first liver-targeted, orally administered drug that can help patients with various types of liver cancer. A phase 1b monotherapy study with fostrox has been completed and a phase 1b/2a combination study in HCC is ongoing..

凭借这种独特的机制，fostrox有可能成为第一种针对肝脏的口服药物，可以帮助各种类型的肝癌患者。fostrox的1b期单药治疗研究已经完成，HCC的1b/2a期联合研究正在进行中。。

About primary liver cancer

关于原发性肝癌

Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high.

原发性肝癌是全球癌症相关死亡的第三大原因，肝细胞癌（HCC）是肝脏中最常见的癌症。虽然现有的晚期肝癌治疗方法可以延长患者的寿命，但治疗效果不足，死亡率仍然很高。

There are approximately 660,000 patients diagnosed with primary liver cancer per year globally and current five-year survival is less than 20 percent1). HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC.

全球每年约有66万名患者被诊断患有原发性肝癌，目前的五年生存率不到20%1）。HCC是一种病因多样的异质性疾病，缺乏在许多其他癌症中观察到的明确突变。这导致分子靶向药物在HCC中缺乏成功。

The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need..

总体效益有限，加上中晚期HCC患者总体预后不佳，导致医疗需求大量未得到满足。。

About Medivir

关于Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.

Medivir开发创新药物，重点关注未满足医疗需求的癌症。候选药物针对可用疗法有限或缺失的适应症领域，并且有很大的机会为患者提供显着改善。Medivir专注于开发福斯特罗西他滨-布拉帕胺（fostrox），这是一种旨在选择性治疗肝癌细胞并最大程度减少副作用的前药。

Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.   1)       Rumgay et al.,European Journal of Cancer 2022 vol.161, 108-118..

合作和伙伴关系是Medivir商业模式的重要组成部分，药物开发由Medivir或合伙进行。Medivir的股票（股票代码：MVIR）在纳斯达克斯德哥尔摩的小盘股名单上上市。1）Rumgay等人，《欧洲癌症杂志2022》第161108-118卷。。

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Main/652/3909338/2538886.pdf

https://mb.cision.com/Main/652/3909338/2538886.pdf

Press release (PDF)

新闻稿（PDF）

SOURCE Medivir

来源Medivir